2-Methylcyclohexaneacetic acid | 6617-04-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Methylcyclohexaneacetic acid
• 英文别名: <2-Methyl-cyclohexyl>-essigsaeure；(2-methyl-cyclohexyl)-acetic acid；(2-Methyl-cyclohexyl)-essigsaeure；1-Methyl-cyclohexan-essigsaeure-(2)；2-(2-methylcyclohexyl)acetic Acid
• CAS: 6617-04-5
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: XZOWBIJUQVPEKP-UHFFFAOYSA-N

物化性质

• 沸点：
  240.47°C (rough estimate)
• 密度：
  1.0120

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Methylcyclohexaneacetic acid 在 phosphorus pentoxide 、 甲苯 作用下， 生成 1-(2-methyl-cyclohexylmethyl)-4,9-dihydro-3H-β-carboline
  参考文献：
  名称：

  3-甲基和3-乙基-2-2'-吡啶基吲哚

  摘要：

  DOI：

  10.1039/jr9550002865
• 作为产物：
  描述：

  2-甲基环己酮 在 palladium on activated charcoal 水 、 氢气 作用下， 以 正己烷 为溶剂， 25.0~160.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 2-Methylcyclohexaneacetic acid
  参考文献：
  名称：

  Stereochemical studies of alkyl methylcyclohexaneacetates with 13C NMR spectroscopy in relation to their attractiveness to the german cockroach.

  摘要：

  所有的甲基甲基环己酸酯的空间异构体被合成出来。它们的非对映异构体对通过制备气相色谱分开。根据它们的13C NMR光谱中环甲基碳的化学位移值，分别将顺式或反式构型分配给这些气相色谱分馏，这些值与相应的二甲基环己烷的值非常接近。通过使用轴向和赤道甲基碳的化学位移值作为参数，确定了热力学上不太稳定的非对映异构体的构象组成。用于生物测试的丙基甲基环己酸酯异构体也以类似方式分开，并通过将其环甲基碳的位移值与甲基酯的值进行比较来确定其构型。通过比较捕获测试评估了非对映异构体对之间的相对活性。结果是：顺式-4-甲基异构体 > 反式-4-甲基异构体；反式-3-甲基异构体 > 顺式-3-甲基异构体；反式-2-甲基异构体 > 顺式-2-甲基异构体。顺式-4-甲基异构体展现出的活性与母体化合物相当。

  DOI：

  10.1271/bbb1961.45.1553

文献信息

• Cycloalkylamides and their therapeutic applications
  申请人：——

  公开号：US20040209858A1

  公开（公告）日：2004-10-21

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of a variety of disorders including, but not limited to, epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, and movement disorders.

  本发明涉及使用式(I)1的化合物治疗多种疾病，包括但不限于癫痫、双相情感障碍、精神障碍、偏头痛、疼痛、神经保护和运动障碍。
• [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY<br/>[FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)
  申请人：ASTRAZENECA AB

  公开号：WO2004013141A1

  公开（公告）日：2004-02-12

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I); G is selected from O, S and NR5; Z is selected from N and CR6; Q1 is selected from optionally substituted aryl and heteroaryl, and the substituents R1 to R6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。
• Stereochemical studies of alkyl methylcyclohexaneacetates with 13C NMR spectroscopy in relation to their attractiveness to the german cockroach.
  作者：Yoshiaki IIDA、Ryozo SUGAWARA

  DOI：10.1271/bbb1961.45.1553

  日期：——

  All positional isomers of methyl methylcyclohexaneacetates were prepared. Their diastereomeric pairs were separated from one another by preparative GLC. Either the cis or trans configuration was assigned to each of these GLC fractions on the basis of the chemical shift values of the ring methyl carbons in their 13C NMR spectra, which were found closely approximate to those of the corresponding dimethylcyclohexanes. The conformational compositions of the thermodynamically less stable diastereomers were determined using the chemical shift values of the axial and equatorial methyl carbons as parameters. The isomers of propyl methylcyclohexaneacetates for the biological test were separated similarly, and their configurations were determined by comparing the shift values of their ring methyl carbons with those of the methyl esters. The relative activity between the diastereomeric pairs was evaluated by a comparative trap test. The result was : cis-4-methyl isomer > trans-4-methyl isomer; trans-3-methyl isomer > cis-3-methyl isomer; and, trans-2-methyl isomer > cis-2-methyl isomer. The cis-4-methyl isomer exhibited activity comparable to that of the parent compound.

  所有的甲基甲基环己酸酯的空间异构体被合成出来。它们的非对映异构体对通过制备气相色谱分开。根据它们的13C NMR光谱中环甲基碳的化学位移值，分别将顺式或反式构型分配给这些气相色谱分馏，这些值与相应的二甲基环己烷的值非常接近。通过使用轴向和赤道甲基碳的化学位移值作为参数，确定了热力学上不太稳定的非对映异构体的构象组成。用于生物测试的丙基甲基环己酸酯异构体也以类似方式分开，并通过将其环甲基碳的位移值与甲基酯的值进行比较来确定其构型。通过比较捕获测试评估了非对映异构体对之间的相对活性。结果是：顺式-4-甲基异构体 > 反式-4-甲基异构体；反式-3-甲基异构体 > 顺式-3-甲基异构体；反式-2-甲基异构体 > 顺式-2-甲基异构体。顺式-4-甲基异构体展现出的活性与母体化合物相当。
• NOVEL COMPOUND AND MEDICAL USE THEREOF
  申请人：Kokubo Masaya

  公开号：US20130245074A1

  公开（公告）日：2013-09-19

  Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.

  提供了一种左多巴前药，它克服了左多巴的血液动力学问题，例如需要大量剂量和频繁给药导致的副作用。其化学名为(2S)-2-氨基-3-(3,4-双((2-(苯甲酰氧基)-2-甲基丙酰氧)苯基)丙酸，其盐或溶剂化合物是左多巴前药，通过口服给药提供了左多巴平稳的血药浓度时间曲线，因此可用作克服左多巴药物制剂相关问题的帕金森病和/或帕金森综合征的预防和/或治疗药物。
• [EN] PART-STREAM DISTILLATION<br/>[FR] DISTILLATION DE FLUX PARTIEL
  申请人：BASF SE

  公开号：WO2016066629A1

  公开（公告）日：2016-05-06

  A continuous process for the preparation of propylene oxide, comprising (a) reacting propene with hydrogen peroxide in a reaction apparatus in the presence of acetonitrile as solvent, obtaining a stream SO containing propylene oxide, acetonitrile, water, at least one further component B wherein the normal boiling point of the at least one component B is higher than the normal boiling point of acetonitrile; (b) separating propylene oxide from SO, obtaining a stream SI containing acetonitrile, water and the at least one further component B; (c) dividing S1 into two streams S2 and S3; (d) subjecting S3 to a vapor-liquid fractionation in a first fractionation unit, obtaining a vapor fraction stream S4 a being depleted, relative to S3, of at least one of the at least one component B and obtaining a liquid bottoms stream S4b, and subjecting at least part of the vapor fraction stream S4 a to a vapor-liquid fractionation in a second fractionation unit, obtaining a vapor fraction stream S4c and a liquid bottoms stream S4 being depleted, relative to S4a, of at least one of the at least one component B; (e) recycling at least a portion of S4, optionally after work-up, to (a).

  一种制备丙烯氧的连续工艺，包括(a)在存在乙腈作为溶剂的反应装置中，将丙烯与过氧化氢反应，得到含有丙烯氧、乙腈、水和至少一种进一步组分B的流SO；(b)从SO中分离丙烯氧，得到含有乙腈、水和至少一种进一步组分B的流SI；(c)将S1分成两个流S2和S3；(d)在第一分馏装置中对S3进行汽液分馏，得到贫化至少一种组分B的汽相流S4a相对于S3，并得到液体底流S4b，并对至少部分汽相流S4a进行第二分馏装置的汽液分馏，得到汽相流S4c和贫化至少一种组分B的液体底流S4；(e)将至少一部分S4回收，可选地经过后续处理后返回(a)。